SCHEMBL2813818

SCHEMBL2813818

NC(=O)CCCCCCC(=O)NO

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 10/20 0.79
HDAC8 Q9BY41 9/20 0.79
HDAC2 Q92769 5/20 0.79
HDAC6 Q9UBN7 5/20 0.79
HDAC3 O15379 4/20 0.79
HDAC5 Q9UQL6 3/20 0.79
HSP90AA1 P07900 1/20 0.62
HDAC11 Q96DB2 3/20 0.50
HDAC10 Q969S8 3/20 0.50
NCOR2 Q9Y618 3/20 0.50
HDAC4 P56524 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
ALOX5 P09917 1/20 0.48
KDM4E B2RXH2 1/20 0.48
BRD4 O60885 1/20 0.48
NCOR1 O75376 1/20 0.48
NR1I2 O75469 1/20 0.48
EGFR P00533 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29055202 1.00 HDAC1 (0.79) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL2810504 1.00 HDAC1 (0.79) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL2808617 0.97 HDAC1 (0.74) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL976350 0.92 HDAC1 (0.65) HDAC1HDAC8HDAC2HDAC6HDAC3
Azelaic Bis Hydroxamic Acid SCHEMBL4741072 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL11767258 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL11769965 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL11764904 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL10439098 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
Suberohydroxamic Acid SCHEMBL2159033 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286583-B Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2024-01-30 CN claimed
CN-116768857-A EZH2/HDAC double-target inhibitor and preparation method and medical application thereof 中国药科大学 2023-09-19 CN claimed
CN-115521228-B BChE and HDAC double-target inhibitor and preparation method and application thereof 中国药科大学 2023-08-22 CN claimed
WO-2026107406-A1 p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF Design Therapeutics, Inc. (US) 2026-05-21 WO disclosed
WO-2025041160-A1 BIFUNCTIONAL CONJUGATE MOLECULES FOR CANCER TREATMENT AND PROCESS OF MAKING THE SAME BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE (BITS), PILANI (IN) 2025-02-27 WO disclosed
US-11981929-B2 Use of small molecules to enhance MAFA expression in pancreatic endocrine cells JANSSEN BIOTECH, INC. (US) 2024-05-14 US disclosed
EP-4347567-A1 TETRAHYDROQUINOLINE (THQ) COUMPOUNDS Centre National de la Recherche Scientifique (FR) 2024-04-10 EP disclosed
CN-115838368-B Hydroxamic acid compound and derivative thereof, preparation method, pharmaceutical composition and application 中国药科大学 2024-02-27 CN disclosed
CN-115286583-B Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2024-01-30 CN disclosed
CN-117327077-A Anilinopyrimidino heterocyclic compound, and preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-01-02 CN disclosed
CN-116903581-A SHP2/HDAC double-target inhibitor and preparation method and application thereof 山东大学 2023-10-20 CN disclosed
WO-2009026446-A9 HDAC INHIBITORS ARQULE, INC. (US) 2010-03-11 WO disclosed
US-7569724-B2 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-08-04 US disclosed
EP-2083005-A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2009-07-29 EP disclosed
WO-2009026446-A2 HDAC INHIBITORS ARQULE, INC. (US) 2009-02-26 WO disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 US disclosed
EP-1598067-A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2005-11-23 EP disclosed
US-20040092598-A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors TOPOTARGET UK LIMITED (GB) 2004-05-13 US disclosed
EP-1335898-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS Prolifix Limited (GB) 2003-08-20 EP disclosed
WO-2002026696-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092598-A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 6/4885HDAC2 8/4885
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives AADAC, BRDT, HDAC5 HDAC1 5/4885HDAC8 36/4885HDAC2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.